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Abstract
Electrochemical immunosensors for ceruloplasmin (Cp) are reported for the first time. Two configurations involving
magnetic beads (MBs) functionalized with Protein A or Streptavidin for immobilization of Cp antibodies were com-
pared, using competitive immunoassay with synthesized alkaline phosphatase-Cp conjugate. Upon capturing MBs-
immunoconjugates onto screen-printed carbon electrodes, quantification of Cp was accomplished by DPV measure-
ment of 1-naphtol generated after 1-naphtyl phosphate addition. Linear ranges of calibration curves and detection
limits were 0.1–1000 mg/mL and 0.040 mg/mL (Protein A-MBs), and 0.025–20 mg/mL and 0.018 mg/mL (Strept-MBs).
Good results were obtained in the determination of Cp in spiked human serum samples.
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1 Introduction
Ceruloplasmin (Cp) is a copper-transporting a2-glyco-pro-
tein also known under the name of ferroxidase because
of its oxidase activity towards ferrous ions [1]. Cp acts as
a source of copper for peripheral organs where this ele-
ment constitutes an essential cofactor for many enzymes
[2]. The normal levels of Cp in serum are 250–470 mg/mL
for women and 250–370 mg/mL for men [3]. The increased
activity of Cp is an index of inflammation while the low
levels (<20 mg/mL in adults) are associated with Wilsons
disease, an infrequent cause of chronic liver disease [4,5].
High concentration levels of Cp are particularly notable
in diseases of the reticuloendithelial system such as Hodg-
kins disease as well as during pregnancy or use of contra-
ceptive pills [6]. Increased urinary excretion of Cp, IgG
and transferrin also predicts future development of mi-
croalbuminuria [7]. Several studies have also reported the
positive correlations of body fat mass or weight gains
with Cp and other inflammation sensitive plasma proteins
(ISPs). It has been proposed that proinflammatory cyto-
kines produced in the adipose tissue increase the hepatic
synthesis of ISPs which are known as important cardio-
vascular diseases risk factors [8].
High serum levels of Cp have been found in patients
with central obesity, these concentrations also being cor-
related with serum triglyceride and cholesterol levels and
visceral fat accumulation [9]. Therefore, Cp among other
ISPs can be used as a biomarker for obesity, particularly
in relation with inflammation-associated proteins [8].
Since Cp has been shown to increase in response to the
atherosclerotic inflammatory process, the determination
of this protein might also be a useful tool to identify pa-
tients with the highest risk for myocardial infarction [9].
Various colorimetric assays for Cp based on the oxidase
activity of this protein with substrates such as p-phenyle-
nediamine (PPD) [10,11] or dianisidine (3,3’-dimethoxy-
benzidine) dihydrochloride [12] were reported in the ear-
lier 70 s. Later, kinetic methods using N,N-dimethyl-p-
phenylenediamine monohydro-chloride (DPPD) [13] or
Fe2+ [14,15] were also described. Turbidimetry [5,16], in-
ductively-coupled plasma mass spectrometry (ICPMS)
[17] and stripping potentiometry [18] were also employed
for the determination of Cp. Different immunoassays for
this protein have been developed and commercial kits
based on such immunoaffinity schemes are currently
available. Some examples are summarized in Table 1,
where the analytical performance of the kits, including in-
formation on the fundamentals of the methodologies,
concentration ranges, limits of detection, precision, type
of samples and assay time, have been collected.
Regarding immunosensors, only one example has been
found in the literature consisting of a reusable piezo-im-
munosensor for Cp based on plasma-polymerized film
(PPF) [19]. Anti-ceruloplasmin antibody (anti-Cp) was
electrostatically adsorbed on the PPF-modified crystal
through an oppositely charged polyelectrolyte layer of al-
ginate. An optimized assay medium containing polyethy-
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lene glycol (PEG) was used to enhance immunosensing
response and a linear concentration range between 0.31
and 27.0 mg/mL with a detection limit of 0.15 mg/mL Cp
were reported (see Table 1).
On the other hand, electrochemical magnetoimmuno-
sensors have demonstrated to be useful bioanalytical
tools combining the excellent capabilities of electrochem-
ical transduction in terms of sensitivity, low cost, rapidity
of the measurements and ability for portable screening
with the special characteristics of functionalized magnetic
beads (MBs) [20–23]. The large active surface area of
MBs enables the immobilization of high antibody load-
ings, and the magnetic properties facilitate the optimiza-
tion of the experimental conditions providing a high sen-
sitivity together with a decrease of matrix effect and mini-
mizing unspecific bindings on the electrode [24].
This paper reports, for the first time, the preparation of
electrochemical immunosensors for Cp. These immuno-
sensors involved the use of functionalized magnetic mi-
croparticles and two different configurations implying
MBs functionalized with protein A or strept-avidin for
the immobilization of anti-Cp or biotinylated-Cp antibod-
ies, respectively were tested and compared. Oriented im-
mobilization onto an electrode surface through protein A
due to its binding capacity with the Fc region of antibod-
ies [25] has demonstrated to lead to highly efficient im-
munoreactions with enhanced performance of the detec-
tion system [26]. Moreover, it is well known that the at-
tachment of proteins through the specific streptavidin
biotin interaction, characterized by a high affinity con-
stant, constitutes also an effective and reliable approach
for the stable immobilization of antibodies [27,28]. The
immunosensor configurations described in this work are
based on competitive type immunoassays involving Cp
and the alkaline phosphatase (AP)labeled Cp conjugate
which was synthesized in the laboratory. Once the immu-
noaffinity reaction occurred on the modified MBs, AP-
Cp/Cp-anti-Cp-Protein A-MBs or AP-Cp/Cp-anti-Cp-
Biotin-Strept-MBs conjugates were captured on the sur-
face of a screen-printed carbon electrode (SPCE) with
a small magnet, and the quantification of Cp was accom-
plished by measuring the differential pulse voltammetric
Table 1. Comparison of the analytical performance of the developed magnetoimmunosensors with various immunoassay systems for
ceruloplasmin (Cp). TMB: 3,3’,5,5’-tetramethylbenzidine; PEG: poly(ethyleneglycol)
Immunoassay system Characteristics Range
(ng/mL)
LOD
(ng/mL)
Precision,
RSD %
Samples Assay
time
Electrochemical magneto-
immunosensor based on
SPCEs (this work)
Competitive immunoassay with anti-
Cp-Protein A-MBs between Cp and
Cp-AP
100–106 40 [a] 5.3 (intra-
assay)
Human serum 50 min
Electrochemical magneto-
immunosensor based on
SPCEs (this work)
Competitive immunoassay with anti-
Cp-Biotin-Strept-MBs between Cp and
Cp-AP
25–
2104
18 [a] 3.2 (intra-
assay)
Human serum 50 min
Assaypro Assay Max
Human Ceruloplasmin
ELISA Kit EC4001–1
Competitive immunoassay with pAb
between Cp and Biotin-Cp. Detect.
with Strept-HRP/TMB
630–
4104
100 [b]
(buffer so-
lution)
4.0 (intra-
assay); 7.0
(inter-assay)
Human plasma,
serum
2 h
47 min
Uscn E90909Hu96 Tests
ELISA Kit (human)
Sandwich immunoassay with mAb and
Biotin-pAb. Detection with Avidin-
HRP and TMB
9.4–600 <3.4 [b] <10 (intra-
assay); <12
(inter-assay
Human serum,
plasma, tissue,
cell culture
3 h
45 min
Uscn C90909Ra96 Tests
ELISA Kit (rat)
Sandwich immunoassay with Ab and
Biotin-Ab. Detection with Avidin-HRP
and TMB
6.25–400 2.01 [b] <10 (intra-
assay); <12
(inter-assay
Rat serum,
plasma, other
biolog. fluids
3 h
45 min
Mybiosource MBS701656 Competitive immunoassay with Ab and
HRP-Ab. Detect. with TMB
(1.5–
50)104
7500 [b]
(buffer so-
lution)
No data Human serum,
plasma
1 h
45 min
Abnova KA0469 Competitive immunoassay with pAb
between Cp and Biotin-Cp. Detect.
with Strept-HRP/TMB
630–
4104
100 [b]
(buffer so-
lution)
4.1 (intra-
assay); 7.2
(inter-assay)
Human plasma,
serum
2 h
47 min
Abnova, KA0470 Sandwich immunoassay with pAb and
Biotin-pAb. Detection with Strept-
HRP and TMB
1.25–320 ~1 [b]
(buffer so-
lution)
4.1 (intra-
assay); 7.1
(inter-assay)
Human urine,
saliva, milk, cell
culture
3 h
40 min
Pro Alt Human Ceruloplas-
min ELISA Quantitation Kit
PRO-20074F
Sandwich immunoassay with Ab and
HRP-Ab. Detection with Avidin-HRP
and TMB
3.9–250 No data No data Human serum,
other biolog.
samples
4h
MDbioproducts Human cer-
uloplasmin MO46029
Competitive immunoassay with pAb
between Cp and Biotin-Cp. Detect.
with Strept-HRP/TMB
630–
2104
<60 [b]
(buffer so-
lution)
4.2 (intra-
assay); 7.3
(inter-assay)
Human serum,
plasma
2h
40 min
Piezoimmunosensor based
on PPF-modified crystal [19]
Immobilization of Ab onto alginate
–PPF QCM. Immuno-assay in the pres-
ence of PEG
310–
2.7104
150 (3s) 6.2 (intra-
assay)
Human serum 2h
15 min
[a] see used equation in the text; [b] minimum detectable concentration.
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(DPV) responses for the enzymatically generated 1-naph-
tol formed upon 1-naphtyl phosphate additions.
2 Experimental
2.1 Reagents and Solutions
A 1.1 mg/mL stock solution of biotinylated anti-cerulo-
plasmin rabbit polyclonal antibody (anti-Cp-Biotin, ran-
domly, non oriented, biotinylated, Abcam) was prepared
by suitable dilution with a PBST buffer solution com-
posed of 10 mM K2HPO4/KH2PO4 buffer of pH 7.4,
2.7 mM KCl and 0.05% Tween 20. A 1.0 mg/mL anti-cer-
uloplasmin (anti-Cp, Abcam) stock solution was also pre-
pared in PBST of pH 8.2. A 7.14 mg/mL stock solution of
human Cp was prepared from the commercial product
(Abcam) with 0.1 M Tris-HCl and 1mM MgCl2, pH 7.2,
solution. Alkaline phosphatase-labeled ceruloplasmin
(AP-Cp) was prepared as described below. 2% (w/v)
bovine serum albumin (BSA, Type H2) and D-biotin sol-
utions were prepared from the commercial products
(Gerbu) dissolved in a 0.1 M Tris-HCl and 1 mM MgCl2
pH 7.2 solution. A Trizma base (Sigma, 99%) and 1 mM
MgCl2 (Panreac, 99%) buffer solution of pH 9.0 (Trizma
buffer) was also employed. 0.05 M 1-naphtylphosphate
(1-NPP, Fluka) solutions were prepared by dilution with
Trizma buffer. Magnetic beads activated with protein A
(Protein A-MBs) or streptavidin (Strept-MBs) (Dyna-
beads) were from Invitrogen. For the cross-reactivity
assays, bilirubin, cholesterol, hemoglobin and human im-
munoglobulin, all from Sigma, were tested.
2.1.1 Sample
The analyzed sample was lyophilized human serum S-
7394 from Sigma spiked with Cp at 1000, 500, 250, 100
and 50 mg/L concentration levels. The solid serum was re-
constituted in 1 mL of Tris-HCl solution of pH 7.2 by
mixing up to total dissolution.
2.2 Apparatus and Electrodes
All electrochemical measurements were carried out using
a PGSTAT 12 potentiostat from Autolab. The electro-
chemical software was the general-purpose electrochemi-
cal system (GPES) (EcoChemie B.V.). Screen-printed
carbon electrodes (4 mm diameter) were purchased from
DropSens (Oviedo, Spain) and used as the working elec-
trodes. These electrodes include a silver pseudo-reference
electrode and a carbon counter electrode. All experi-
ments were performed in an incubator at T=25 8C. A P-
Selecta ultrasonic bath, an Optic Ivymen System constant
temperature incubator shaker (Comecta S.A.) and a P-Se-
lecta Agimatic magnetic stirrer, all distributed by Schar-
lab, were also used. pH measurements were made with
a precision Metrohm Herisau E-510 pH-meter. A Vortex
(Heidolph) stirrer, a neodimium magnet (AIMAN GZ)
and a DynaMag-2 magnetic separator (Invitrogen, Dynal
AS) were also used.
2.3 Procedures
2.3.1 Preparation of Alkaline Phosphatase-Labeled
Ceruloplasmin (AP-Cp)
The Easy Link Alkaline Phosphatase Conjugation kit (3
100 mg/L, Abcam) was used to prepare AP-Cp following
the instructions from the supplier. Briefly, 50 mL of 2 mg/
mL Cp solution were treated with 5 mL of the modifier in
an Eppendorf tube. Then, the resulting solution was
added to the AP mix vial and allowed reacting for three
hours at 25 8C. Thereafter, 5 mL of quencher solution
were added and left to stand for 30 min. Finally, 50 mL of
glycerol preservative were added. The resulting solution
contained 1 mg/mL AP-Cp in 50% (v/v) glycerol.
2.3.2 Preparation of the Anti-Cp-Protein A-MBs and
Anti-Cp-Biotin-Strept-MBs Immunosensors
1 mL (30 mg) of the Protein A-MBs suspension or 3 mL
(30 mg) of the Strept-MBs suspension were added to
a 1.5-mL Eppendorf tube, washed twice with PBST
buffer solution of pH 8.2 or 7.4, respectively, and re-sus-
pended in 25 mL of a 2.5 mg/mL anti-Cp solution in PBST
buffer of pH 8.2 (Protein A-MBs), or in 25 mL of a 10 mg/
mL anti-Cp-Biotin solution in PBST buffer of pH 7.4
(Strept-MBs). Each washing step consisted of a resuspen-
sion of the beads in the washing solution and gentle stir-
ring for 1 min followed by separation with the magnet for
2 min and removal of the solution. After incubation at
25 8C under stirring at 950 rpm for 15 minutes, anti-Cp-
Protein A-MBs or anti-Cp-Biotin-Strept-MBs conjugates
were sequentially washed with B&W buffer solution of
pH 8.2 or pH 7.4, respectively, and with Tris-HCl buffer
solution. Then, 25 mL of a mixture of 5 mg/mL AP-Cp and
Cp of variable concentration in Tris-HCl (Protein A-
MBs), or 1 mg/mL AP-Cp and Cp of variable concentra-
tion in Tris-HCl and 2% BSA (Strept-MBs), were added
and incubation was performed for 30 minutes at 25 8C
under continuous stirring. Thereafter, AP-Cp/Cp-anti-Cp-
Protein A-MBs or AP-Cp/Cp-anti-Cp-biotin-Strept-MBs
conjugates were washed three times with Tris-HCl buffer
and re-suspended in Trizma buffer of pH 9. Then, 45 mL
of the corresponding suspension were transferred onto
the surface of a SPCE, where MBs bearing the immuno-
conjugates were captured by placing a small neodimium
magnet on the bottom part of the electrode. Finally, 5 mL
of the 50 mM 1-naphthyl-phosphate solution were added
to the electrode surface and, after reaction for 5 minutes,
a differential pulse voltammogram (step potential=
0.005 V, amplitude=0.07 V) was recorded between 0.15
and +0.60 V vs. Ag. Unless otherwise mentioned, all
measurements were carried out in triplicate.
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3 Results and Discussion
A scheme of the immobilized immunoconjugates on the
electrode surface and the electrochemical transduction
step is illustrated in Figure 1. The experimental proce-
dures described in Section 2.3.2 involved anti-Cp immobi-
lization on Protein A-MBs and biotinylated anti-Cp anti-
body immobilization on Strept-MBs. Thereafter, in both
cases, competitive-type immunoassays were employed in-
volving Cp and AP-Cp. The immuno-conjugates com-
posed of APCp/Cp-anti-Cp-Protein A-MBs or AP-Cp/
Cp-anti-Cp-Biotin-Strept-MBs were then retained onto
a SPCE surface by means of a small neodymium magnet
located at the bottom part of the electrode. The affinity
reaction was monitored by adding 1-naphtylphosphate as
the AP substrate and measuring at the SPCE the differ-
ential pulse voltammetric (DPV) oxidation peak of 1-
naphtol generated in the AP enzyme reaction.
3.1 Optimization of the Performance Conditions of the
anti-Cp-Protein A-MBs and Anti-Cp-Biotin-Strept-
MBs Immunosensors
The experimental variables affecting the analytical perfor-
mance of both magnetoimmunosensor designs for Cp
were optimized. The amount of functionalized MBs was
fixed to 30 mg taking into account previous results [29]. In
the case of the anti-Cp-Protein A-MBs configuration, the
optimization studies included the influence of: a) the an-
tibody loading onto the functionalized MBs for various
AP-Cp concentrations ranging between 1 and 50 mg/mL,
in the absence of Cp; b) the anti-Cp loading for different
Cp concentrations at the AP-Cp concentration corre-
sponding to the saturation level; c) the incubation time of
anti-Cp onto Protein A-MBs; d) the time needed for
competition between Cp and AP-Cp; e) the 1-naphthyl-
phosphate concentration; f) the time required for the AP
enzyme reaction to proceed. Details on these optimiza-
tion studies can be found in the text and Figures S1 and
S2 of Supporting Information. The variables ranges
checked and the selected values for all of them are sum-
marized in Table 2. Similarly, the following experimental
variables affecting the voltammetric response of the anti-
Cp-Biotin-Strept-MBs immunosensors were optimized: a)
the loading of biotinylated antibody onto the Strept-MBs
using 1 mg/mL.
AP-Cp; b) the concentration of AP-Cp; c) the incuba-
tion time of anti-Cp-Biotin onto Strept-MBs; d) the 1-
naph-thyl-phosphate concentration; e) the time required
for the AP enzyme reaction to proceed. Figures S3 and
S4 in Supplementary material show the experimental
graphs obtained with these studies. Table 2 also summa-
rizes the tested ranges and the selected values.
Looking at Table 2, it is interesting to notice that the
optimum concentrations of antibody and AP-Cp are dif-
ferent in both configurations (larger and smaller, respec-
tively, for the anti-Cp-Biotin-Strept-MBs immunosen-
sors). This is most likely due to the differences in the abil-
ity for the antibody orientation with both functionalized
MBs. So, when Protein A-MBs are used, an oriented anti-
body immobilization is produced and a lower loading is
required to cover the MBs binding sites.
Moreover, a higher AP-Cp concentration will be
needed to saturate the binding positions of the antibodies.
On the contrary, when anti-Cp-Biotin-Strept-MBs are
constructed, the antibody immobilization is not oriented
and, consequently, it is less efficient and a higher concen-
tration to obtain the largest response is required. At this
Fig. 1. Schematic display of the electrochemical immunosensors for Cp using (A) AP-Cp/Cp-anti-Cp-Protein A-MBs or (B) AP-Cp/
Cp-anti-Cp-Biotin-Strept-MBs conjugates.
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situation, a lower concentration of AP-Cp is needed. In
the case of anti-Cp-Biotin-Strept-MBs immunosensors,
we observed experimentally that a blocking step with 2%
BSA was necessary in order to minimize nonspecific bind-
ing of immunoreagents. This was in agreement with the
findings obtained by other authors [30].
3.2 Analytical Characteristics of the
Magnetoimmunosensors
Figure 2 compares the calibration plots constructed for
Cp using both AP-Cp/Cp-anti-Cp-Protein A-MBs/SPCE
(a) or AP-Cp/Cp-anti-Cp-Biotin-Strept-MBs/SPCE (b)
immunosensor configurations under the optimized work-
ing conditions stated above. The displayed error bars
were calculated from measurements carried out with
three different immunosensors in each case. The ip vs. Cp
immunosensors-concentration curve was fitted by nonlin-
ear regression using the Sigma Plot data analysis soft-
ware. The adjusted equation (r=0.997 in both cases) was:
y ¼ imin þ imaximin ½1þ ðEC50=xÞk ð1Þ
where imax and imin are the maximum and minimum peak
current values in the calibration graph (see Table 3). The
EC50 values, which correspond to the Cp concentration
producing a fifty per cent competition, were 4.71.8 and
0.90.1 mg/mL for the Protein A-MBs and the Strept-
MBs immunosensor configurations, respectively, with Hill
slope values, h, of 0.400.06 and 0.510.06, respec-
tively. The ranges of linearity were between 0.1 and
1000 mg/mL (r=0.995) with the immunosensor using Pro-
tein A-MBs, and between 0.025 and 20 mg/mL (r=0.993)
for the anti-Cp-Biotin-Strept-MBs immunosensor. The
Table 2. Optimization of the performance conditions of the anti-Cp-Protein A-MBs (a) and anti-Cp-Biotin-Strept-MBs (b)
Range evaluated Selected value
(a) Tested variable
Anti-Cp (mg/mL) 0–10 2.5
AP-Cp (mg/mL) 1–50 5
Incubation time of anti-Cp onto Protein A-MBs (min) 15–60 15
Time needed for competition between Cp and AP-Cp (min) 15–60 30
1-Naphthylphosphate concentration (mM) 0.5–100 5
Time required for the AP enzyme reaction to proceed (min) 0–12 5
(b) Tested variable
Anti-Cp-Biotin (mg/mL) 1–20 10
AP-Cp (mg/mL) 0.5–5 1
Incubation time of anti-Cp-Biotin onto Strept-MBs (min) 15–60 15
Time needed for competition between Cp and AP-Cp (min) 15–60 30
1-Naphthylphosphate concentration (mM) 0.5–100 5
Time required for the AP enzyme reaction to proceed (min) 0–12 5
Fig. 2. Calibration plots constructed for Cp using AP-Cp/Cp-anti-Cp-Protein A-MBs/SPCE (a) and AP-Cp/Cp-anti-Cp-Biotin-Strep-
MBs/SPCE (b).
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achieved limits of detection, 0.04 and 0.018 mg/mL, re-
spectively, were calculated from the equation:
LOD ¼ EC50 fimaximin ðimaximin3sÞ11g1=h ð2Þ
where s is the standard deviation (n=10) of the zero
value (the ip value measured in the absence of Cp,
0.08 mA or 0.05 mA, respectively). Furthermore, quan-
tification limits can be estimated as the lowest analyte
concentration that can be measured in the linear portion
of the corresponding calibration plots (0.1 and 0.025 mg/
mL for AP-Cp/Cp-anti-Cp-Protein A-MBs/SPCE and
AP-Cp/Cp-anti-Cp-Biotin-Strept-MBs/SPCE immunosen-
sors, respectively). The differences found in the analytical
characteristics obtained with both magnetoimmunosensor
designs arise probably from the above mentioned orient-
ed or not oriented antibody immobilization. As men-
tioned already, the immunosensor using Protein A-MBs
required a larger AP-Cp loading to saturate the oriented
anti-Cp antibody.
Therefore, the competition of the analyte with AP-Cp
was less favorable thus giving rise to a higher upper Cp
concentration in the calibration graph as well as to higher
limit of detection. On the contrary, a smaller AP-Cp load-
ing was needed to saturate the not oriented anti-Cp-
Biotin immobilized on Strept-MBs with the consequent
easier competition between AP-Cp and Cp and the lower
upper concentration in the calibration plot and the calcu-
lated limit of detection.
The reproducibility of the DP voltammetric measure-
ments was evaluated with different immunosensors fabri-
cated in the same day for solutions containing no Cp.
Relative standard deviation (RSD) values of 5.2 and
3.2% (n=8) were obtained for the anti-Cp-Protein A-
MBs and anti-Cp-Biotin-Strept-MBs immunosensors, re-
spectively. These values demonstrated the reliability of
the immunosensor preparation procedures for both con-
figurations.
These analytical characteristics were compared with
those reported for the different immunoassay systems col-
lected in Table 1. As it can be seen, the developed elec-
trochemical magnetoimmunosensors provided the widest
analytical linear ranges as well as limits of detection rank-
ing among the lowest despite the difficulty of this com-
parison due to the different criteria used for LOD calcu-
lation. In addition, the immunosensors provided precise
results with low RSD values. In particular, the anti-Cp-
Biotin-Strept-MBs immunosensor provided the lowest
RSD value among the reported data.
Moreover, a relevant advantageous difference relied on
the short assay time requiring only 50 min for the immu-
noconjugate preparation and the competitive immunoas-
say including the coupled enzyme reaction. Therefore, the
whole assay, including the voltammetric detection, can be
performed in approximately one hour which is much
shorter than the time required for the immunoassays
listed in Table 1. The storage stability of the anti-Cp-Pro-
tein A-MBs and anti-Cp-Biotin-Strept-MBs immunocon-
jugates in 0.1 M Tris-HCl or PBST solution at 8 8C was in-
vestigated. Various immunoconjugates were prepared on
the same day, stored and used to construct the corre-
sponding immunosensors in different days. As an exam-
ple, Figure 3 shows the control chart for the currents mea-
sured with the anti-Cp-Biotin-Strept-MBs magnetoimmu-
nosensors for solutions containing no Cp upon storage in
both buffer solutions. As it can be seen, the current was
below the lower limit of control after seven days of stor-
age (Figure 3a), and then decreased when the immuno-
sensors were stored in 0.1 M Tris-HCl, which was attribut-
ed to the observed magnetoimmunoconjugate agglutina-
tion. On the contrary, magnetoimmunosensors prepared
with immunoconjugates stored in PBST (Figure 3b) pro-
vided measurements inside the control limits for at least
42 days. This largely improved stability was probably due
to the effect of the Tween 20 surfactant present in PBST
which enhanced the microparticles dispersion avoiding
their agglutination. It is important to remark that this sta-
bility permits the preparation of one batch of immuno-
conjugates, their storage under the described conditions,
and the fabrication of the immunosensor just before the
analysis is performed. For example, this protocol allows
a single determination to be made in approximately
35 min when using anti-Cp-Biotin-Strept-MBs. Similar re-
sults were obtained for studies on the storage stability
with anti-Cp-Protein A-MBs immunosensors.
3.3 Selectivity Studies
Figure 4 shows the responses obtained with both magne-
toimmunosensor designs in serum containing no Cp and
Table 3. Analytical characteristics of the magnetoimmunosensors constructed for Cp using anti-Cp-Protein A-MBs or anti-Cp-Biotin-
Strept-MBs conjugates.
Conjugate anti-Cp-Protein A-MBs anti-Cp-Biotin-Strept-MBs
Linear range (mg/mL) 0.1–1000
r=0.995
0.025–20
r=0.993
EC50 (mg/mL) 4.71.8 0.90.1
Hill slope 0.400.06 0.510.06
imin (mA) 0.940.09 0.0540.05
imax (mA) 2.840.07 1.280.03
LOD (mg/mL) 0.04 0.018
r 0.996 0.997
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diluted with Tris-HCl buffer to different dilution ratios.
As it can be observed, a strong matrix effect occurred in
both cases. However, while this effect could be complete-
ly removed upon a 1 :1000 dilution for the immunosen-
sors prepared with anti-Cp-Biotin-Strept-MBs, any dilu-
tion was sufficient to avoid the matrix effect in the case
of anti-Cp-Protein A-MBs. These results were attributed
to the high selectivity of the Biotin-Streptavidin bond
preventing the interaction with other serum proteins.
Taking into account this behavior,
only the immunosensor using the anti-Cp-Biotin-
Strept-MBs conjugate was employed for the analysis of
the serum sample.
In order to go more deeply into the observed decrease
in the immunosensor response at low serum dilutions, the
effect of various species: bilirubin, hemoglobin, cholester-
ol, albumin and human serum immunoglobulin, which
may be present in biological fluids together with Cp, was
tested. The obtained results for solutions containing no
Cp and different concentration levels of the checked com-
pounds, corresponding to those expected in serum at
1 :1000 or 1 :100 dilutions (1 :10 in the case of albumin)
are summarized in Figure 5.
Moreover, according to the specifications of the suppli-
er, the effect of the presence of sodium ion was also eval-
uated. As it can be observed, the immunosensor respons-
es were similar in all cases to that measured in the ab-
sence of the other proteins or cholesterol, thus demon-
strating the excellent selectivity for the determination of
Cp in biological fluids. Particularly interesting is the
effect of sodium ion. Although the presence of this ion at
1.5 and 15 mM, which corresponded to the expected
levels in serum diluted at 1 :100 and 1 :10 ratios, respec-
tively, produced a slight decrease in the immunosensor re-
sponse, no noticeable effect was observed at the ion con-
centration level for the selected 1 :1000 dilution factor.
Therefore, it can be concluded that the immunosensor se-
lectivity was very good under the conditions employed
for the determination of Cp in human serum.
3.4 Determination of Cp in Human Serum
As commented above, the anti-Cp-Biotin-Strept-MBs/
SPCE magnetoimmunosensor was used for the determi-
nation of Cp in spiked human serum samples. Firstly,
a calibration plot was constructed from the reconstituted
sample, 1 : 1000 diluted, and containing Cp in the 0.05 to
Fig. 3. Control charts constructed to check the stability of anti-
Cp-Biotin-Strept-MBs conjugates upon storage in (a) Tris-HCl
and (b) PBST buffer solutions. The central value was set as the
average response obtained for eight measurements of different
solutions containing no Cp; upper and lower limits of control
were set as3the standard deviation of these measurements.
Fig. 4. Effect of human serum dilution with Tris-HCl buffer on
the DPV response in the absence of Cp measured with AP-Cp/
Cp-anti-Cp-Protein A-MBs/SPCE (a) and AP-Cp/Cp-anti-Cp-
Biotin-Strept-MBs/SPCE immunosensors.
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1.00 mg/mL concentration range. As it is displayed in
Figure 6, the voltammetric responses (black dots) were
very similar to the measurements obtained with Cp stan-
dard solutions. In fact, the respective slope values of the
linear plots were (0.300.2) and (0.300.1) mA.
Therefore, interpolation of the DP voltammetric meas-
urements for the sample into the calibration plot con-
structed with Cp standard solutions was employed to
quantify Cp. Samples were analyzed by triplicate at five
concentration levels (see Table 4) with mean recoveries
ranging between 91 and 104%. These results demonstrat-
ed the usefulness of the developed magnetoimmunosen-
sor for the analysis of Cp in serum with just an appropri-
ate dilution as sample treatment. Moreover, it should be
remarked that the high sensitivity of the developed meth-
odology allowed the determination of Cp in serum at the
clinically relevant concentration levels despite the 1 :1000
dilution factor of the sample.
4 Conclusions
Electrochemical immunosensors for the determination of
Cp have been reported for the first time. The develop-
ment of these immunosensors profited from the advanta-
geous properties of functionalized MBs to carry out the
immunoreactions on their surface and not on the electro-
chemical transducer surface, thus avoiding unspecific
bindings on the electrode. Two different configurations
involving MBs functionalized with Protein A or streptavi-
din were developed and analytically compared. The ana-
lytical performance of the magnetoimmunosensors can be
positively compared in terms of wide linear range, limits
of detection, precision and short assay time with that
claimed for different immunoassay kits. It is important to
remark that the storage stability of the anti-Cp-Biotin-
Fig. 5. Selectivity studies for AP-Cp/Cp-anti-Cp-Biotin-Strept-MBs/SPCE immunosensors. DPV responses obtained in the absence
of Cp. See text for details.
Fig. 6. A comparison of the linear portions of the calibration
plots constructed for Cp in reconstituted 1: 1000 diluted human
serum (black dots), and standard Cp solutions (white dots).
Table 4. Determination of Cp in spiked human serum with AP-
Cp/Cp-anti-Cp-Strept-MBs/SPCE immunosensor.
Cp (mg/mL) Cp found (mg/mL) Recovery (%)
0.05 0.0500.003 1015
0.10 0.0940.006 946
0.25 0.230.02 947
0.50 0.450.04 918
1.00 1.040.07 1047
[a] Concentration in the analytical solution.
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Strept-MBs allows the determination to be carried in ap-
proximately 35 min, which is a much shorter assay time
than that reported for the immunoassays. Therefore, the
anti-Cp-Biotin-Strept-MBs immunosensor appears to be
highly appropriate for the analysis of Cp at clinically rele-
vant concentrations in human serum samples. Only an ap-
propriate dilution with buffer was needed as sample treat-
ment to avoid any matrix effect. Although this dilution
increases the detection limit attainable in the analysis of
serum with respect to that calculated in buffer solutions,
the excellent sensitivity of the developed magnetoimmu-
nosensor allows the determination of Cp to be carried
out at the clinically relevant levels in a rapid and simple
manner.
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